The novel strategy to overcome the drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells
Drug Resistance Updates · 2026
DOI: 10.1016/j.drup.2025.101316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Lingmin Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Fifth Affiliated Hospital, The Affiliated Panyu Central Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target…. Hauptthemen laut MEDLINE: Lung Neoplasms, Drug Resistance, Neoplasm, Cancer-Associated Fibroblasts, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Guangzhou Medical University, National Key Research and Development Program of China, Guangzhou Municipal Science and Technology Program key projects.
Abstract (Originalsprache)
Current pharmacotherapy on the fatal lung cancer is often limited by the development of drug resistance, which significantly contributes to treatment failure. The drug resistance in cancer is associated with tumor microenvironment (TME), particularly with cancer-associated fibroblasts (CAFs). However, the present approaches show little progress in the eliminating lung cancer cells and reversing the TME synergistically. The emergence of nanomedicine offers promising strategies to overcome this challenge. In this study, we developed a proteolysis-targeting chimeras (PROTAC)-based nanodrug, designed to eliminate both lung cancer cells and CAFs, thereby amplifying the therapeutic effects. This nanodrug was constructed by loading dBET6 with US Food and Drug Administration (FDA) approved polymer Poly(lactic-co-glycolic acid) (PLGA), and further camouflaged with the hybrid membranes derived from platelet and lung cancer cells (PLMPD). PLMPD demonstrated excellent dual-targeting capabilities to both lung cancer cells and CAFs, leading to significant apoptosis in both cell types in vitro. We also found that PLMPD could inhibited the growth of Osimertinib-resistant cells. In vivo studies revealed that PLMPD enhanced tumor targeting, effectively inhibited tumor growth, and reversed the tumor-promoting TME in the lung cancer xenograft models. These findings underscore the potential of PLMPD as a promising PROTAC-based nanodrug for lung cancer therapy, offering a new avenue for overcoming drug resistance and improving treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Fifth Affiliated Hospital, The Affiliated Panyu Central Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respira…
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
- Department of Oncology, The First Affiliated Hospital, Hengyang Medical School University of South China, Hengyang 421000, China. Electronic address: liyuehua2020@stu.usc.edu.cn.
Förderung
- Guangzhou Medical University
- National Key Research and Development Program of China
- Guangzhou Municipal Science and Technology Program key projects
- National Natural Science Foundation of China
Zitieren
APA
Zhang, L., He, L., Lin, Y., Wei, J., Tang, S., Lei, X., Lin, X., Zhou, D., Fu, L., Li, Y., He, J., Liang, L., & Yu, X. Y. (2026). The novel strategy to overcome the drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101316
Vancouver
Zhang L, He L, Lin Y, Wei J, Tang S, Lei X, et al. The novel strategy to overcome the drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2025.101316
BibTeX
@article{Zhang2026,
author = {Zhang, Lingmin and He, Linlong and Lin, Yinshan and Wei, Juyan and Tang, Shiqi and Lei, Xueping and Lin, Xufeng and Zhou, Dazhi and Fu, Liwu and Li, Yuehua and He, Juyun and Liang, Lu and Yu, Xi-Yong},
title = {The novel strategy to overcome the drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells},
journal = {Drug Resistance Updates},
year = {2026},
doi = {10.1016/j.drup.2025.101316}
}
EUVIMED